Drug Profile
Epilepsy therapeutic - Marathon Pharmaceuticals
Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Marathon Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Epilepsy
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for phase-I development in Epilepsy(In adolescents, In children, In infants) in USA
- 18 Jan 2016 Phase-I clinical trials in Epilepsy (In infants, In children, In adolescents) in USA (unspecified route)